SE0201662D0 - Pharmaceutical combination - Google Patents

Pharmaceutical combination

Info

Publication number
SE0201662D0
SE0201662D0 SE0201662A SE0201662A SE0201662D0 SE 0201662 D0 SE0201662 D0 SE 0201662D0 SE 0201662 A SE0201662 A SE 0201662A SE 0201662 A SE0201662 A SE 0201662A SE 0201662 D0 SE0201662 D0 SE 0201662D0
Authority
SE
Sweden
Prior art keywords
compound
pharmaceutical combination
pharmaceutically
derivateive
complicaiton
Prior art date
Application number
SE0201662A
Other languages
English (en)
Swedish (sv)
Inventor
Ann-Charlotte Roth
Elisabeth Svernhage
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0201662A priority Critical patent/SE0201662D0/xx
Publication of SE0201662D0 publication Critical patent/SE0201662D0/xx
Priority to TW092113322A priority patent/TW200307686A/zh
Priority to JP2004509650A priority patent/JP2005532345A/ja
Priority to RU2004131868/15A priority patent/RU2004131868A/ru
Priority to AU2003232711A priority patent/AU2003232711A1/en
Priority to US10/516,426 priority patent/US20060052314A1/en
Priority to CNA038117347A priority patent/CN1656066A/zh
Priority to EP03756136A priority patent/EP1513807A1/en
Priority to BR0311138-5A priority patent/BR0311138A/pt
Priority to PL03373409A priority patent/PL373409A1/xx
Priority to PCT/SE2003/000854 priority patent/WO2003101956A1/en
Priority to MXPA04011910A priority patent/MXPA04011910A/es
Priority to CA002486110A priority patent/CA2486110A1/en
Priority to ARP030101881A priority patent/AR040138A1/es
Priority to NO20044673A priority patent/NO20044673L/no
Priority to ZA200408787A priority patent/ZA200408787B/xx
Priority to IL16516904A priority patent/IL165169A0/xx
Priority to CO04120030A priority patent/CO5631429A2/es
Priority to IS7581A priority patent/IS7581A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE0201662A 2002-05-31 2002-05-31 Pharmaceutical combination SE0201662D0 (sv)

Priority Applications (19)

Application Number Priority Date Filing Date Title
SE0201662A SE0201662D0 (sv) 2002-05-31 2002-05-31 Pharmaceutical combination
TW092113322A TW200307686A (en) 2002-05-31 2003-05-16 Pharmaceutical combination
CA002486110A CA2486110A1 (en) 2002-05-31 2003-05-27 Pharmaceutical combination
BR0311138-5A BR0311138A (pt) 2002-05-31 2003-05-27 Produto combinado, método de preparação do mesmo, kit de partes, método de tratamento de arritmia, e, usos de um produto combinado e de um composto
MXPA04011910A MXPA04011910A (es) 2002-05-31 2003-05-27 Combinacion farmaceutica.
AU2003232711A AU2003232711A1 (en) 2002-05-31 2003-05-27 Pharmaceutical combination
US10/516,426 US20060052314A1 (en) 2002-05-31 2003-05-27 Pharmaceutical combination
CNA038117347A CN1656066A (zh) 2002-05-31 2003-05-27 联合药物
EP03756136A EP1513807A1 (en) 2002-05-31 2003-05-27 Pharmaceutical combination
JP2004509650A JP2005532345A (ja) 2002-05-31 2003-05-27 薬学的組み合わせ
PL03373409A PL373409A1 (en) 2002-05-31 2003-05-27 Pharmaceutical combination
PCT/SE2003/000854 WO2003101956A1 (en) 2002-05-31 2003-05-27 Pharmaceutical combination
RU2004131868/15A RU2004131868A (ru) 2002-05-31 2003-05-27 Фармацевтическая комбинация
ARP030101881A AR040138A1 (es) 2002-05-31 2003-05-28 Combinacion de compuestos, conjunto de partes (kit), metodo para preparar un conjunto de partes (kit) y uso de dicha combinacion de compuestos en la fabricacion de un medicamento
NO20044673A NO20044673L (no) 2002-05-31 2004-10-28 Farmasoytisk kombinasjon
ZA200408787A ZA200408787B (en) 2002-05-31 2004-10-29 Pharmaceutical combination.
IL16516904A IL165169A0 (en) 2002-05-31 2004-11-11 A combination of thrombin inhibitor of a particular class or a pharmaceutically-acceptable derivative thereof and certain antiarrhythmic oxabispidinesor pharmaceutically-acceptable salts thereof
CO04120030A CO5631429A2 (es) 2002-05-31 2004-11-29 Combinacion farmaceutica
IS7581A IS7581A (is) 2002-05-31 2004-12-03 Lyfjasamsetning

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0201662A SE0201662D0 (sv) 2002-05-31 2002-05-31 Pharmaceutical combination

Publications (1)

Publication Number Publication Date
SE0201662D0 true SE0201662D0 (sv) 2002-05-31

Family

ID=20288040

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0201662A SE0201662D0 (sv) 2002-05-31 2002-05-31 Pharmaceutical combination

Country Status (19)

Country Link
US (1) US20060052314A1 (pt)
EP (1) EP1513807A1 (pt)
JP (1) JP2005532345A (pt)
CN (1) CN1656066A (pt)
AR (1) AR040138A1 (pt)
AU (1) AU2003232711A1 (pt)
BR (1) BR0311138A (pt)
CA (1) CA2486110A1 (pt)
CO (1) CO5631429A2 (pt)
IL (1) IL165169A0 (pt)
IS (1) IS7581A (pt)
MX (1) MXPA04011910A (pt)
NO (1) NO20044673L (pt)
PL (1) PL373409A1 (pt)
RU (1) RU2004131868A (pt)
SE (1) SE0201662D0 (pt)
TW (1) TW200307686A (pt)
WO (1) WO2003101956A1 (pt)
ZA (1) ZA200408787B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401539D0 (sv) 2004-06-15 2004-06-15 Astrazeneca Ab New compounds
AR057064A1 (es) 2005-06-13 2007-11-14 Astrazeneca Ab Compuestos para el tratamiento de arritmias cardiacas, formulacion farmaceutica y preparacion del compuesto
AR053901A1 (es) * 2005-06-20 2007-05-23 Astrazeneca Ab Formas fisicas de oxabispidinas n,n'- disustituidas
JP5114880B2 (ja) 2006-07-06 2013-01-09 ダイキン工業株式会社 新規α−フルオロメトキシカルボン酸エステル、該α−フルオロメトキシカルボン酸エステルの製造方法及びセボフルランの製造方法
US9802954B2 (en) 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
CN108314624B (zh) * 2017-01-17 2022-09-27 东莞东阳光科研发有限公司 一种多氟苯胺的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9903759D0 (sv) * 1999-10-18 1999-10-18 Astra Ab Pharmaceutically active compounds
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios

Also Published As

Publication number Publication date
IL165169A0 (en) 2005-12-18
RU2004131868A (ru) 2005-10-10
NO20044673L (no) 2004-12-07
TW200307686A (en) 2003-12-16
JP2005532345A (ja) 2005-10-27
EP1513807A1 (en) 2005-03-16
ZA200408787B (en) 2005-10-20
CA2486110A1 (en) 2003-12-11
PL373409A1 (en) 2005-08-22
CO5631429A2 (es) 2006-04-28
AR040138A1 (es) 2005-03-16
WO2003101956A1 (en) 2003-12-11
MXPA04011910A (es) 2005-03-31
BR0311138A (pt) 2005-03-01
US20060052314A1 (en) 2006-03-09
CN1656066A (zh) 2005-08-17
IS7581A (is) 2004-12-03
AU2003232711A1 (en) 2003-12-19

Similar Documents

Publication Publication Date Title
BR0215240A (pt) Derivados de calcona e seu uso no tratamento de doenças
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
GB0005251D0 (en) Therapeutic compounds
ATE346039T1 (de) Sulfonamido-substituierte verbrückte bicycloalkylderivative
NO20060971L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
EA200500853A1 (ru) 2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
BG106825A (en) Substituted oxazolidinones and their use in the field of blood coagulation
GB0225474D0 (en) Therapeutic agents
BRPI0512253A (pt) composto, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto combinado, e, processo para a preparação de um composto
DK1288205T3 (da) Nye phenylalanin-derivater
BRPI0512252A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto combinado, e, processo para a preparação de um composto
ZA200508889B (en) Pyrrolidino-1,2-dicarboxy-1-(phenylamide)-2-(4-(3-oxomorpholino-4-yl)-phenylamide) derivatives and related compounds for use as inhibitors of coagulation factor Xa in the treatment of thrombo-embolic diseases
DE502004005033D1 (de) Substituierte 2-aminotetraline zur behandlung von depressionen
TR200200716T2 (tr) Ketiyapin granülleri
CY1110130T1 (el) Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α.
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
ATE396986T1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
BR0213037A (pt) Derivados de pirimidina
SE0201662D0 (sv) Pharmaceutical combination
DK1174131T3 (da) Anvendelse af et middel til forbedring af astrocytfunktion til behandling af Parkinsons sygdom
GB0522908D0 (en) Therapeutic agents
PL369737A1 (en) Derivatives of phenoxy-n-'4-(isothiazolidin-1,1-dioxid-2yl)phenyl-valerian- acid amide and other compounds as inhibitors of the coagulation factor xa in the treatment of thromboembolic diseases and tumors
NO20032006D0 (no) Anvendelse av melagatran for fremstilling av et medikament for behandling av ischemiske lidelser